Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Poly(ADP-Ribose) Polymerase Inhibitors [MoA]

Known as: Poly ADP Ribose Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase Inhibitors, Poly ADP-Ribose Polymerase Inhibitors 
 
National Institutes of Health

Related topics

Related topics

6 relations
Poly(ADP-Ribose) Polymerase Inhibitor [EPC]Poly(ADP-ribose) Polymerase Inhibitorsolaparibolaparib 50 MG Oral Capsule
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract P6-08-21: Prevalence of HER2 positivity in germline BRCA 1/2-associated breast cancers (gBRCA1/2-BC)
Purpose: To define the prevalence of HER2 positive breast cancer (HER2+ BC) in women with gBRCA1/2-BC and to determine whether… Expand
Is this relevant?
2019
2019
Abstract 3501: Entinostat enhances the efficacy of olaparib in preclinical models of ovarian cancer
Introduction: Ovarian cancer is a rare but often fatal disease and a leading cause of gynecologic cancer death, in the United… Expand
Is this relevant?
2018
2018
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
OBJECTIVE Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP… Expand
Is this relevant?
Review
2018
Review
2018
Principles of clinical management of ovarian cancer.
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is… Expand
Is this relevant?
2018
2018
Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions
Poly(ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics with enhanced selectivity and cytotoxicity in BRCA1/2… Expand
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARPI… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1996
1996
Lactate stimulation of macrophage-derived angiogenic activity is associated with inhibition of Poly(ADP-ribose) synthesis.
Injury and inflammation lead to hypoxia and elevated lactate in wounds. This redox environment establishes cells in a reparative… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE